Literature DB >> 35550541

Monocyte/High-Density Lipoprotein Ratio Is an Indicator of Activity in Patients with Ulcerative Colitis.

Mehmet Suat Yalçın1, Serkan Yalaki2, Şehmus Ölmez3, Adnan Taş3.   

Abstract

BACKGROUND: In patients with ulcerative colitis, endoscopic and clinical indices are used to assess the disease activity. In addition, stud- ies have been carried out for easier and cheaper markers in recent years. For this purpose, we evaluated the monocyte/high-density lipoprotein ratio of the disease activity.
METHODS: According to clinical activity and partial Mayo scores, a total of 114 patients, 53 in the active ulcerative colitis group and 61 in the ulcerative colitis remission group were included in the study. Monocyte/high-density lipoprotein ratio, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, C-reactive protein, and erythrocyte sedimentation rate measurements of these 2 groups were recorded. Ulcerative colitis remission group and active ulcerative colitis group were compared in terms of activity.
RESULTS: The monocyte/high-density lipoprotein ratio value in the active ulcerative colitis group was significantly higher than that of the ulcerative colitis remission group (10.68 ± 3.39, 6.68 ± 1.39, P < .001, respectively). The monocyte/high-density lipoprotein ratio value for active ulcerative colitis at a cut-off value of 7.4 had 83% sensitivity and 81% specificity. In the active ulcerative colitis group, neutrophil/lymphocyte ratio, C-reactive protein, and erythrocyte sedimentation rate values were significantly higher than the ulcerative colitis remission group (P < .001, P < .001, P < .001, respectively).
CONCLUSION: Monocyte/high-density lipoprotein ratio is an inexpensive and effective marker that can be used to determine the activity of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35550541      PMCID: PMC9153283          DOI: 10.5152/tjg.2022.21401

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  7 in total

1.  Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease.

Authors:  H Kundi; E Kiziltunc; M Cetin; H Cicekcioglu; Z G Cetin; G Cicek; E Ornek
Journal:  Herz       Date:  2016-01-11       Impact factor: 1.443

2.  Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation.

Authors:  Ugur Canpolat; Elif Hande Çetin; Serkan Cetin; Selahattin Aydin; Mehmet Kadri Akboga; Cagri Yayla; Osman Turak; Dursun Aras; Sinan Aydogdu
Journal:  Clin Appl Thromb Hemost       Date:  2015-07-01       Impact factor: 2.389

3.  Assessment of monocyte to high density lipoprotein cholesterol ratio and lymphocyte-to-monocyte ratio in patients with metabolic syndrome.

Authors:  Demir Vahit; Mehmet Kadri Akboga; Yilmaz Samet; Ede Hüseyin
Journal:  Biomark Med       Date:  2017-07-07       Impact factor: 2.851

Review 4.  Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases.

Authors:  Shiva Ganjali; Antonio M Gotto; Massimiliano Ruscica; Stephen L Atkin; Alexandra E Butler; Maciej Banach; Amirhossein Sahebkar
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

5.  Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes.

Authors:  Alice Ossoli; Alan T Remaley; Boris Vaisman; Laura Calabresi; Monica Gomaraschi
Journal:  Biochem J       Date:  2015-11-10       Impact factor: 3.857

6.  Susceptibility to Ulcerative Colitis and Genetic Polymorphisms of A251G SOD1 and C-262T CAT.

Authors:  Gadier El-Kheshen; Maryam Moeini; Mostafa Saadat
Journal:  J Med Biochem       Date:  2016-07-06       Impact factor: 3.402

7.  A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio.

Authors:  Suleyman Sayar; Kemal Kurbuz; Resul Kahraman; Zuhal Caliskan; Roni Atalay; Oguzhan Ozturk; Hamdi Levent Doganay; Kamil Ozdil
Journal:  North Clin Istanb       Date:  2019-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.